US-based Dexcom has unveiled its plan to connect its Dexcom G6 Real-Time Continuous Glucose Monitoring System (rt-CGM) with the Omnipod 5 Automated Insulin Delivery (AID) system in Germany.
Dexcom G6 has a small, wearable sensor and transmitter to give patients real-time glucose readings without the need to scan or prick their finger. It is designed to continuously measure and transmit glucose levels wirelessly to a smart device or receiver.
It is now said to be the first and only CGM that connects to the Omnipod 5 AID system in Germany to protect users against high and low glucose levels.
With this announcement, the diabetes management company has strengthened its position as the most connected CGM in the world with the Dexcom G6.
It will provide type 1 diabetes Germans with another AID option by including a new AID product into its CGM ecosystem, Dexcom said.
Dexcom EMEA & LATAM senior vice president and general manager Alex Moussa said: “For over a decade, Dexcom has been the sensor of choice for the development of AID systems.
“Dexcom has supported more than 50 studies around the world ranging from early academic projects to increasingly sophisticated trials in collaboration with industry partners, safely powering AID systems for over one million patient-years of cumulative use.
“Our CGM systems were the first to enable industry-leading connectivity and we now link with over 60 connected partners worldwide.”
Dexcom G6 is said to be the only device utilised in the clinical studies that resulted in the regulatory clearance of Omnipod 5 in Europe and the US, showing Dexcom’s potential in integrating connected systems.
In research published in Diabetes Care, Dexcom G6 with Omnipod 5 significantly decreased time in hypoglycaemia and HbA1c in very young children with Type 1 diabetes, the diabetes management firm said.
Dexcom intends to give users flexibility and choice when it comes to how they read their glucose data and administer insulin as the most connected CGM in the world.
In July this year, the company received approval from Health Canada for its next-generation Dexcom G7 CGM system for all types of diabetes patients aged two years and older.
